ERSP

Electronic Retailing Self-Regulation Program

ERSP Reviews Advertising for ‘Androfen,’ Recommends Marketer Modify or Discontinue Certain Claims; Find Marketer Can Support Certain Claims

ERSP has recommended that Androfen, LLC, modify or discontinue certain advertising claims for Androfen, a dietary supplement intended to increase testosterone levels. ERSP also determined that certain claims were supported by the advertiser’s evidence.

Read More

ERSP Refers Advertising for Nick Vertucci Real Estate Academy to FTC After Marketer Declines to Participate in ERSP Inquiry

ERSP will refer direct response advertising for Nick Vertucci Real Estate Academy to the Federal Trade Commission (FTC) after the marketer, The Nick Vertucci Companies, Inc., respectfully declined to participate in an ERSP inquiry.

Read More

ERSP Recommends Obesity Research Institute Modify, Discontinue Certain Claims for Lipozene

ERSP has recommended that Obesity Research Institute, LLC, modify or discontinue certain advertising claims for Lipozene, a weight loss supplement.

Read More

ERSP Recommends Real Freedom, Inc. Modify, Discontinue Certain Claims for Real Estate Mogul; Company Agrees to Do So

ERSP has recommended that Real Freedom, Inc., modify or discontinue certain claims for the Real Estate Mogul real estate investing education program, including claims related to earnings.

Read More

ERSP Reviews Advertising for ‘Jidue,’ Recommends Marketer Modify or Discontinue Certain Claims

ERSP has recommended that Audy Global modify or discontinue claims for “Jidue,” a facial massager intended to help reduce eye puffiness, facial tension, and wrinkles.

Read More

ERSP Refers Advertising for Kelacore to FTC, FDA: Marketer Fails to Respond to ERSP Inquiry

ERSP has announced it will refer direct response advertising for the dietary supplement “Kelacore” to the FTC and FDA after the marketer, Nature's Medicine Associates, failed to respond to an ERSP inquiry.

Read More